News

News

Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

Talking Biotech: Treating Mental Illness through Nasal Drug Delivery - Shawn Singh
Talking Biotech: Treating Mental Illness through Nasal Drug Delivery - Shawn Singh
Read
Bio Report logo
The Bio Report: A Rapid Onset Nasal Spray to Treat Mental Health Conditions
Read
The Biotech Project
The Biotech Project: Featuring Shawn Singh
Read

Press Releases

Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely recognition comes during Mental Health Awareness Month and MHA’s nationwide efforts to fight stigma and provide support around mental health SOUTH
Results from new study further support that fasedienol acts locally in the nasal passages and does not require systemic uptake or direct activity on neurons in the brain to achieve fast-acting anti-anxiety effects SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that
Vistagen plans to use the LSAS as the primary efficacy endpoint for a Phase 3 clinical study designed to evaluate fasedienol as a treatment for the overall control of symptoms of social anxiety disorder (SAD) FDA provides helpful guidance on key aspects of potential NDA-enabling development plan in